Lowest Price Guaranteed From USD 3,499
Published
July 2018
Pages
548
View Count
7038
Report Description
In my opinion, when it comes to CAR-T cells, every detail matters, including the CAR construct, type of disease targeted, type of cytokine used to culture the cells, condition of the patients, and their pre-treatment history, taking into consideration the patient’s heart and kidney function. As the therapy is new, people have not yet understood how to handle the side-effects; however, I believe that eventually we will learn to take care of these toxicities as we treat more patients
-Principle Investigator, US based academic research institute
Amidst the current initiatives to develop more targeted anti-cancer therapies, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent and viable therapeutic intervention to eradicate tumor cells, with minimal side effects. It is based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells. There are certain key characteristics that render CAR-T cells suitable for use as effective therapeutic tools; these include target specificity, adaptability and the capability to retain immunologic memory.
Close to 70 academic and research institutes across the globe have made significant contributions to this field, mostly by convening the initial research on potential product candidates. These efforts have built the intellectual framework for the establishment of several start-ups. The ongoing innovation has also led to the discovery of several novel molecular targets, strengthening the research pipelines of various companies engaged in this domain. Given the recent approval of two CAR-T therapies, namely Kymriah® (Novartis) and Yescarta® (Gilead Sciences), and a robust development pipeline, the CAR-T therapy market also offers considerable promise to a number of industry stakeholders.
Scope of the Report
The “CAR-T Therapies Market, 2018-2030” report features an extensive study of the current market landscape and the future potential of CAR-T therapies. One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing development programs of both small and big pharmaceutical firms. Amongst other elements, the report features the following:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. The report includes information on (potential) sales-based revenues of CAR-T therapies that are currently marketed or are in late stages of development. Additionally, it presents detailed segmentation of the overall opportunity on the basis of geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, hepatocellular carcinoma and non-Hodgkin’s lymphoma). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the CAR-T therapy market in the short to mid-term and long term.
Chapter 3 provides a general overview of CAR-T therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the conception and historical evolution of cancer immunotherapy, general manufacturing procedures used for the production of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapeutic options.
Chapter 4 focuses on CAR-T therapies and highlights the prevailing trends pertaining to the ongoing research in this field. It features details on the historical development of CAR-T products, such as the structure of CAR-T constructs (including information on all four generations of CAR-Ts), a discussion on the process of CAR-T development, molecular targets that are currently under investigation (for the development of such therapeutic products) and the current challenges (such as toxicity issues) that are associated with this therapy segment.
Chapter 5 provides insights on the popularity of CAR-T therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2017, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords and drug candidates, as observed on social media.
Chapter 6 provides information on around 366 CAR-T cell therapies that are currently in different stages of development (clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules with respect to the type of developer(s), phase of development, target therapeutic areas and disease indications, key target antigens, source of T-cells (autologous and allogenic) and route of administration (intravenous infusion and regional route). Further, the chapter identifies the most active players ( in terms of number of pipeline candidates ) and features a logo landscape representation, highlighting product developers in North America, Europe and the Asia Pacific region. In addition, it includes an analysis of the CAR constructs that are presently being used in clinical stage CAR-T therapies on the basis of generation of CAR product, type of binding domain, type of vector and type of co-stimulatory domain.
Chapter 7 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular targets of CAR-T therapies being developed against hematological cancers and solid tumors. Further, the chapter includes an analysis of global CAR-T trials that were registered in the time period between 2009 to 2018, featuring the year wise trend and distribution of CAR-T trials across different geographies. In addition, it includes a comprehensive analysis of close to 290 clinical trials (completed / ongoing) to evaluate CAR-T therapies with respect to the phase of development, patient segment (children, adults and senior citizens), and type of therapy (monotherapy and combination therapy). To offer due credit to the work of eminent researchers in this domain, we have also mapped the presence of key opinion leaders (who are involved in this field of research) across the globe.
Chapter 8 includes detailed profiles of approved / late stage CAR-T therapies. Each profile features a general overview of the therapy and provides information on its history of development, clinical trial timeline, clinical trial results, manufacturing process, estimated cost of treatment and treatment regimen details.
Chapter 9 highlights the most common therapeutic indications targeted by CAR-T therapies, and features brief discussions on the CAR-T therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.
Chapter 10 provides a list of technology platforms that are either available in the market or under development, for designing and / or manufacturing CAR-T therapies. It features brief profiles of some of the key technologies; each profile contains details on the various pipeline molecules that have been / are being developed using the technology, its advantages and the associated partnerships.
Chapter 11 provides insights on the cell therapy manufacturing process, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining such manufacturing sites. It includes a list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house capabilities. For all the players mentioned in this chapter, we have included details on location of manufacturing facilities, products manufactured, scale of operation and compliance to cGMP standards.
Chapter 12 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement considerations for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapies.
Chapter 13 features an elaborate discussion on the commercial opportunity associated with CAR-T therapies. It provides a comprehensive market forecast analysis for therapies that are either already approved or are in the mid-phases of clinical development (phase I/II, phase II and phase III), taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed segmentation of the opportunity on the basis of geography (North America, Europe and Asia Pacific) and target indications (acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, hepatocellular carcinoma and non-Hodgkin’s lymphoma).
Chapter 14 highlights the key promotional strategies that are being implemented by the developers of the marketed products, Kymriah® and Yescarta®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.
Chapter 15 includes brief company profiles of the leading players in the CAR-T therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T therapies, affiliated technology portfolio ( if available ), recent developments related to CAR-T therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 17 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Enkhtsetseg Purev (Assistant Professor Of Medicine, University Of Colorado), Miguel Forte (Chief Operating Officer, TxCell), Vincent Brichard (Vice President, Immuno-Oncology, Celyad) and Xian-Bao Zhan (Professor Of Medicine and Director, Department Of Oncology, Changhai Hospital).
Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 19 is an appendix, which contains the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Immunotherapy, an Emerging Therapeutic Option
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell Based Therapies
3.6. Evolution of T-Cell Immunotherapies
3.7. Key Considerations for T-Cell Immunotherapies
3.8. Strategies Employed for Redirection of T-Cells
3.9. Manufacturing of Engineered T-Cells
3.10. T-Cell Transduction / Transfection Methods
3.10.1. Retroviral Vectors
3.10.2. Lentiviral Vectors
3.10.3. Non-viral Transfection Methods
3.10.3.1. Sleeping Beauty Transposon
3.11. T-Cell Immunotherapy: Targeted Therapeutic Areas
3.12. T-Cell Immunotherapies: Key Challenges
4. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY
4.1. Chapter Overview
4.2. History of Development
4.3. Anatomical Layout of Chimeric Antigen Receptor
4.4. Development Of CAR-T Therapies
4.5. Universal CAR-Ts
4.6. Preferred Routes of Administration
4.7. Toxicity Issues
4.7.1. Cytokine Release Syndrome (CRS)
4.7.2. On-Target, Off-Tumor Toxicity
4.7.3. Encephalopathy and B-Cell Aplasia
4.7.4. Neurological Toxicity
4.7.5. Anaphylaxis
4.7.6. Insertional Oncogenesis
4.7.7. Graft versus Host Disease (GVHD)
4.8. Management of Toxicity Issues
4.8.1. Pharmacological Immunosuppression
4.8.2. Target Selection
4.8.3. Safety Switches
4.8.4. Elimination Genes
4.8.5. Receptor Expression
4.9. CD19: An Attractive Target
4.10. Other Targets
4.11. Challenges Associated with CAR-T Therapy
4.11.1. Competitive Risks
4.11.2. Clinical Risks
4.11.3. Regulatory Risks
4.11.4. Commercial Risks
5. EMERGING TRENDS ON SOCIAL MEDIA
5.1. Chapter Overview
5.2. Trends on Twitter
5.2.1. Social Media Analysis: Yearly Trends on Twitter
5.2.2. Social Media Analysis: Popular Keywords on Twitter
5.3. Social Media Analysis: Most Popular Drugs on Twitter
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. CAR-T Therapies: Pipeline Overview
6.2.1. Distribution by Type of Developer
6.2.2. Distribution by Phase of Development
6.2.3. Target Oncological Indications
6.2.3.1. Popular Target Indications
6.2.4. Popular Target Antigens
6.2.5. Distribution by Source of T-Cells
6.2.6. Distribution by Route of Administration
6.2.7. Key Industry Players
6.2.8. Key Non-Industry Players
6.3. CAR-T Therapies: Analysis of CAR Constructs
6.3.1. Analysis by Generation of CAR-T Therapies
6.3.2. Analysis by Type of scFv Antibody
6.3.3. Analysis by Type of Vector
6.3.4. Analysis by Type of Co-Stimulatory Domain(s)
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. CAR-T Therapies: Analysis by Popularity of Target Antigens
7.2.1. Hematological Cancers: Popular Targets
7.2.1.1. CD19 CAR-T Therapies: Competitive Landscape
7.2.1.2. CD19 CAR-T Therapies: Clinical Trial Results of Prominent Product Candidates
7.2.1.3. BCMA CAR-T Therapies: Competitive Landscape
7.2.1.4. BCMA CAR-T Therapies: Clinical Trial Results of Prominent Product Candidates
7.2.2. Solid Tumors: Popular Targets
7.2.2.1. Meso CAR-T Therapies: Competitive Landscape
7.2.2.2. GD2 CAR-T Therapies: Competitive Landscape
7.3. CAR-T Therapies: Clinical Trial Trends, 2009-2018
7.3.1. Analysis by Trial Registration Year
7.3.2. Geographical Analysis by Number of Registered Trials
7.4. CAR-T Therapies: Clinical Trial Overview
7.4.1. Clinical Trial Analysis: Distribution by Phase of Development
7.4.2. Clinical Trial Analysis: Distribution by Patient Segment
7.4.3. Clinical Trial Analysis: Distribution by Type of Therapy
7.5. CAR-T Therapies: Key Opinion Leaders
7.5.1. Most Prominent Key Opinion Leaders
8. MARKETED AND LATE-STAGE CAR-T THERAPY PROFILES
8.1. Chapter Overview
8.2. Kymriah® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. History of Development
8.2.3. Current Development Status
8.2.4. Key Clinical Trial Results
8.2.5. Dosage Regimen, Price and Manufacturing
8.3. Yescarta® / Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.3.5. Next Generation eACT CAR Candidates
8.4. JCAR (Juno Therapeutics)
8.4.1. Therapy Overview
8.4.2. CAR-T Design
8.4.3. Development Status
8.4.4. Key Clinical Results
8.4.4.1. JCAR014
8.4.4.2. JCAR017
8.4.4.3. JCAR018
8.4.5. Dosage Regimen and Manufacturing
8.5. CAR-T Series (Cellular Biomedicine Group)
8.5.1. Therapy Overview
8.5.2. History of Development
8.5.3. Current Development Status
8.5.4. Key Clinical Trial Results
8.5.4.1. CBM-EGFR.1
8.5.4.2. CBM-C19.1
8.5.4.1. CBM-C20.1
8.5.4.2. CBM-C30.1
8.5.5. Dosage Regimen and Manufacturing
8.5.6. Patent Portfolio
8.6. CD19 CAR (Takara Bio)
8.6.1. Therapy Overview
8.6.2. Current Developmental Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. Dual Targeting CAR-T Cell therapies (Autolus)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. CAR-T Therapies (Sinobioway Cell Therapy)
8.8.1. Therapy Overview
8.8.2. Current Development Status
9. KEY THERAPEUTIC AREAS CAR-T THERAPIES
9.1. Chapter Overview
9.2. Hematological Malignancies
9.2.1. Leukemia and Lymphoma
9.2.1.1. Leukemia: Introduction and Epidemiology
9.2.1.1.1. Acute Myeloid Leukemia (AML)
9.2.1.1.2. Chronic Myeloid Leukemia (CML)
9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.2.1.2. Lymphoma: Introduction and Epidemiology
9.2.1.3. Current Treatment Landscape
9.2.1.3.1. Targeted Therapies
9.2.1.4. CAR-T Therapy and Research Landscape
9.2.2. Multiple Myeloma
9.2.2.1. Introduction and Epidemiology
9.2.2.2. Current Treatment Landscape
9.2.2.3. CAR-T Therapy and Research Landscape
9.3. Solid Tumors
9.3.1. Metastatic Melanoma
9.3.1.1. Introduction and Epidemiology
9.3.1.2. Current Treatment Landscape
9.3.1.3. CAR-T Therapy and Research Landscape
9.3.2. Lung Cancer
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. CAR-T Therapy and Research Landscape
9.3.3. Bladder Cancer
9.3.3.1. Introduction and Epidemiology
9.3.3.2. Current Treatment Landscape
9.3.3.3. CAR-T Therapy and Research Landscape
9.3.4. Kidney Cancer
9.3.4.1. Introduction and Epidemiology
9.3.4.2. Current Treatment Landscape
9.3.4.3. CAR-T Therapy and Research Landscape
9.3.5. Ovarian Cancer
9.3.5.1. Introduction and Epidemiology
9.3.5.2. Current Treatment Landscape
9.3.5.3. CAR-T Therapy and Research Landscape
9.3.6. Breast Cancer
9.3.6.1. Introduction and Epidemiology
9.3.6.2. Current Treatment Landscape
9.3.6.3. CAR-T Therapy and Research Landscape
10. EMERGING TECHNOLOGIES
10.1. Chapter Overview
10.2. Genome Editing Technologies
10.2.1. Technology Overview
10.2.2. Applications
10.2.3. Emerging Technology Platforms Used in CAR-T Therapies
10.2.3.1. CRISPR/Cas9 System
10.2.3.1.1. Key Components and Function
10.2.3.1.2. Mechanism of Action
10.2.3.1.3. Targeting Efficiency and Challenges
10.2.3.1.4. Next-GEN CRISPR Technology
10.2.3.1.5. Technology Providers
10.2.3.2. TALENs
10.2.3.2.1. Key Components and Function
10.2.3.2.2. Mechanism of Action
10.2.3.2.3. Advantages and Challenges
10.2.3.2.4. Technology Providers
10.2.3.3. megaTAL
10.2.3.3.1. Technology Providers
10.2.3.4. Zinc Finger Nuclease
10.2.3.4.1. Technology Providers
10.3. Designing T-Cell Therapies with Improved Characteristics
10.3.1. Technologies for Targeting Multiple Cancers
10.3.1.1. NKR-T Platform (Celyad)
10.3.2. Technologies for Improved Safety
10.3.2.1. Armored CAR and EGFRt technology (Juno Therapeutics)
10.3.2.2. RheoSwitch Therapeutic System (Intrexon)
10.3.2.3. Inducible Caspase 9 Safety Switch (Bellicum Pharmaceuticals)
10.3.2.3.1. CaspaCIDe Technology
10.3.2.3.2. CIDeCAR Technology
10.3.2.3.3. GoCAR-T Technology
10.3.2.4. On-Off Switch, Multiple Companies
10.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
10.3.2.4.2. On-Off Switch (Theravectys)
10.3.2.5. Other Technologies to Improve CAR-T Safety
10.3.3. Allogeneic Technologies
10.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
10.3.3.2. Allogeneic Platform (Celyad)
10.3.3.3. Allogeneic Platform (Cellectis)
11. CASE STUDY: CELL THERAPY MANUFACTURING
11.1. Chapter Overview
11.2. Introduction
11.3. Key Challenges
11.4. Current Trends
11.4.1. Companies with In-House Capabilities
11.4.2. Contract Manufacturers
11.5. Key Considerations for a Manufacturing Site
11.6. Regulatory Landscape
12. T-CELL IMMUNOTHERAPY: COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Factors Contributing to the Price of Cell / Gene Therapies
12.3. Pricing Models for T-Cell Immunotherapies
12.3.1. On the Basis of Associated Costs
12.3.2. On the Basis of Competition
12.3.3. On the Basis of Patient Segment
12.3.4. On the Basis of Expert Opinions
12.4. Reimbursement Considerations for T-Cell Immunotherapies
12.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapy
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Forecast Methodology
13.4. Overall CAR-T Therapy Market
13.4.1. CAR-T Therapy Market: Distribution by Geography
13.4.2. CAR-T Therapy Market: Distribution by Target Indications
13.5. CAR-T Therapy Market: Product-Wise Sales Forecasts
13.5.1. Kymriah® (Novartis)
13.5.1.1. Target Population
13.5.1.2. Sales Forecast
13.5.2. Yescarta® (Gilead Sciences)
13.5.2.1. Target Population
13.5.2.2. Sales Forecast
13.5.3. bb2121 (Celgene / bluebird bio)
13.5.3.1. Target Population
13.5.3.2. Sales Forecast
13.5.4. MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center)
13.5.4.1. Target Population
13.5.4.2. Sales Forecast
13.5.5. CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
13.5.5.1. Target Population
13.5.5.2. Sales Forecast
13.5.6. GPC3 CAR-T (Shanghai GeneChem)
13.5.6.1. Target Population
13.5.6.2. Sales Forecast
13.5.7. TBI-1501 (Takara Bio / Jichi Medical University)
13.5.7.1. Target Population
13.5.7.2. Sales Forecast
13.5.8. JCAR017 (Juno Therapeutics / Celgene)
13.5.8.1. Target Population
13.5.8.2. Sales Forecast
13.5.9. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
13.5.9.1. Target Population
13.5.9.2. Sales Forecast
13.5.10. PCAR-019 (PersonGen BioTherapeutics)
13.5.10.1. Target Population
13.5.10.2. Sales Forecast
13.5.11. AUTO2 (Autolus)
13.5.11.1. Target Population
13.5.11.2. Sales Forecast
13.5.12. AUTO3 (Autolus)
13.5.12.1. Target Population
13.5.12.2. Sales Forecast
13.5.13. BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital)
13.5.13.1. Target Population
13.5.13.2. Sales Forecast
13.5.14. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology / Henan Cancer Hospital)
13.5.14.1. Target Population
13.5.14.2. Sales Forecast
13.5.15. CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University)
13.5.15.1. Target Population
13.5.15.2. Sales Forecast
13.5.16. LCAR-B38M CAR-T (Nanjing Legend Biotech)
13.5.16.1. Target Population
13.5.16.2. Sales Forecast
13.5.17. CD19 CAR-T (Shanghai Bioray Laboratory)
13.5.17.1. Target Population
13.5.17.2. Sales Forecast
14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Support Services and Informative Downloads
14.5. Kymriah®: Promotional Analysis
14.5.1. Drug Overview
14.5.2. Product Website Analysis
14.5.2.1. Messages for Healthcare Professionals
14.5.2.2. Messages for Patients
14.5.3. Patient Support Services and Informative Downloads
14.5.4. Other Promotional Activities
14.5.4.1. Presence in Conferences
14.6. Yescarta®: Promotional Analysis
14.6.1. Drug Overview
14.6.2. Product Website Analysis
14.6.2.1. Messages for Healthcare Professionals
14.6.2.2. Messages for Patients
14.6.3. Patient Support Services and Informative Downloads
14.6.4. Other Promotional Activities
14.6.4.1. Presence in Conferences
15. COMPANY PROFILES
15.1. Chapter Overview
15.2. Autolus
15.3. bluebird bio
15.4. CARsgen Therapeutics
15.5. Celgene
15.6. Cell Medica
15.7. Cellectis
15.8. Cellular Biomedicine Group
15.9. Innovative Cellular Therapeutics
15.10. Kite Pharma (A Gilead Sciences Company)
15.11. Novartis
15.12. Sinobioway Cell Therapy
15.13. Takara Bio
15.14. ZIOPHARM Oncology
16. CONCLUSION
16.1. CAR-T Therapies Market is Characterized by a Robust Pipeline of Over 350 Product Candidates Being Developed for Various Oncological Indications
16.2. The Primary Focus of CAR-Based Therapeutic Interventions is on Hematological Malignancies and Solid Tumors
16.3. Both Established Players and Start-Ups are Actively Involved in Developing CAR-T Therapies; Academic Institutes Continue to Make Significant Contributions to the Innovation in this Domain
16.4. Several Innovative Technology Platforms have been Developed, and are Expected to Enable the Development of Better Therapies, With Favorable Safety and Efficacy Profiles
16.5. Owing to High R&D Investments, CAR-T Therapies Bear Premium Price Tags; Developers are Striving to Offer Reimbursement Plans and Implement Various Promotional Strategies to Achieve Commercial Success
16.6. Post the Approval of Multiple Late-Phase Product Candidates, the Market is Anticipated to Grow at a Rapid Pace in the Foreseen Future
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Enkhtsetseg Purev, Assistant Professor of Medicine, University of Colorado (Q1 2018)
17.3. Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology, Changhai Hospital (Q4 2017)
17.4. Brian Dattilo, Manager of Business Development, Waisman Biomanufacturing (Q1 2017)
17.5. Miguel Forte, Chief Operating Officer, TxCell (Q3 2016)
17.6. Adrian Bot, Vice President, Scientific Affairs, Kite Pharma (Q1, 2016)
17.7. Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development, Theravectys (Q3, 2015)
17.8. Vincent Brichard, Vice President, Immuno-Oncology, Celyad (Q3 2015)
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 The Four Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 3Es of the Immune System
Figure 3.5 Strategies Employed for the Redirection of T-Cells
Figure 3.6 T-Cell Manufacturing: General Procedure
Figure 3.7 T-Cell Immunotherapies: Targeted Therapeutic Areas
Figure 3.8 T-Cell Immunotherapies: Benefits and Key Challenges
Figure 4.1 Historical Timeline: Development of CAR-T cells
Figure 4.2 CAR-T: Structure and Domains
Figure 4.3 CAR Generations: Structural Layout
Figure 4.4 Development of CAR-T Therapies
Figure 4.5 Challenges Associated with CAR-T Therapy
Figure 5.1 Social Media Analysis: Twitter Trends, January 2012-November 2017
Figure 5.2 Social Media Analysis: Popular Keywords on Twitter, January 2012-November 2017
Figure 5.3 Social Media Analysis: Twitter, Most Popular Candidates, January 2012-November 2017
Figure 6.1 CAR-T Therapy Pipeline: Distribution by Type of Developer
Figure 6.2 CAR-T Therapy Pipeline: Distribution by Phase of Development
Figure 6.3 CAR-T Therapy Pipeline: Distribution by Target Therapeutic Area
Figure 6.4 CAR-T Therapy Pipeline: Popular Target Indications
Figure 6.5 CAR-T Therapy Pipeline: Distribution by Target Antigen
Figure 6.6 CAR-T Therapy Pipeline: Distribution by Source of T-Cells
Figure 6.7 CAR-T Therapy Developer Landscape: Distribution by Source of T-Cells
Figure 6.8 CAR-T Therapy Pipeline: Distribution by Route of Administration
Figure 6.9 CAR-T Therapy Pipeline: Active Industry Players in Clinical Development
Figure 6.10 CAR-T Therapy Pipeline: Active Industry Players in Preclinical Development
Figure 6.11 CAR-T Therapy Pipeline: Active Non-Industry Players in Clinical Development
Figure 6.12 CAR-T Therapy Pipeline: Active Non-Industry Players in Preclinical Development
Figure 6.13 CAR-Construction: Distribution by Generation of CAR-T Therapies
Figure 6.14 CAR-Construction: Distribution by Type of scFv Used in CAR-T Therapies
Figure 6.15 CAR-Construction: Distribution by Type of Vector
Figure 6.16 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 7.1 CAR-T Therapies: Popular Targets in Hematological Cancer
Figure 7.2 CAR-T Therapies: Popular Targets in Solid Tumor
Figure 7.3 CAR-T Clinical Trials: Cumulative Trend (2009-2018)
Figure 7.4 CAR-T Clinical Trials: Geographic Landscape (Pre-2016 and 2018)
Figure 7.5 CAR-T Therapies: Distribution of Clinical Trials by Phase of Development
Figure 7.6 CAR-T Therapies: Distribution of Clinical Trials by Patient Segment
Figure 7.7 CAR-T Therapies: Distribution of Clinical Trials by Type of Therapy
Figure 7.8 CAR-T Therapies: Geographical Distribution of Key Opinion Leaders
Figure 7.9 CAR-T Therapies: Prominent Key Opinion Leaders
Figure 8.1 Kymriah®: Industry Sponsored Clinical Trial Design
Figure 8.2 Kymriah®: Non-Industry Sponsored Clinical Trial Design
Figure 8.3 Yescarta®: Clinical Trial Design
Figure 8.4 Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 8.5 JCAR Series: Industry Sponsored Clinical Trial Design
Figure 8.6 JCAR Series: Non-Industry Sponsored Clinical Trial Design
Figure 8.7 Cellular Biomedicine’s CAR-T Series: Clinical Trial Design
Figure 8.8 Takara Bio’s CD19 CAR-T: Clinical Trial Design
Figure 8.9 Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
Figure 8.10 Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Design
Figure 9.1 Leukemia: Classification
Figure 9.2 Leukemia: Global Epidemiological Distribution
Figure 9.3 Lymphoma: Global Epidemiological Distribution
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5 Melanoma: Global Epidemiological Distribution
Figure 9.6 Lung Cancers: Classification
Figure 9.7 Lung Cancer: Global Epidemiological Distribution
Figure 9.8 Bladder Cancer: Global Epidemiological Distribution
Figure 9.9 Kidney Cancer: Global Epidemiological Distribution
Figure 9.10 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.11 Breast Cancer: Global Epidemiological Distribution
Figure 10.1 Genome Editing Technologies: Applications
Figure 10.2 Genome Editing: Emerging Technology Platforms Used in CAR-T Therapies
Figure 10.3 Key Technologies to Enhance Features / Characteristics of CAR-T Therapies
Figure 10.4 Cellectis: Properties of Enhanced T-Cell Platform
Figure 10.5 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 11.1 Cell Therapy Manufacturing: Key Steps
Figure 11.2 Cell Therapy Manufacturing: Scenarios
Figure 11.3 T-Cell Immunotherapy Manufacturing: Key Collaborations
Figure 12.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 13.1 Overall CAR-T Therapy Market Forecast, 2018-2030: Base Scenario (USD Billion)
Figure 13.2 CAR-T Therapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Figure 13.3 CAR-T Therapy Market: Distribution by Target Indication, 2018, 2025 and 2030 (USD Billion)
Figure 13.4 Kymriah® (Novartis): Current Status of Development
Figure 13.5 Kymriah® (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.6 Yescarta® (Gilead Sciences): Current Status of Development
Figure 13.7 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.8 bb2121 (Celgene / bluebird bio): Current Status of Development
Figure 13.9 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.10 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center): Current Status of Development
Figure 13.11 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.12 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University): Current Status of Development
Figure 13.13 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.14 GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 13.15 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.16 TBI-1501 (Takara Bio / Jichi Medical University): Current Status of Development
Figure 13.17 TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.18 JCAR017 (Juno Therapeutics / Celgene): Current Status of Development
Figure 13.19 JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.20 IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 13.21 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.22 PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 13.23 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.24 AUTO2 (Autolus): Current Status of Development
Figure 13.25 AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.26 AUTO3 (Autolus): Current Status of Development
Figure 13.27 AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.28 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital): Current Status of Development
Figure 13.29 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.30 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital): Current Status of Development
Figure 13.31 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.32 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University): Current Status of Development
Figure 13.33 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.34 LCAR-B38M CAR-T (Nanjing Legend Biotech): Current of Development
Figure 13.35 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 13.36 CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 13.37 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 14.1 Promotional / Marketing Strategy: Product Website Analysis
Figure 14.2 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 14.3 Product Website Analysis: Kymriah®, Messages for Healthcare Professionals
Figure 14.4 Product Website Analysis: Kymriah®, Messages for Patients
Figure 14.5 Product Website Analysis: Kymriah®, Patient Support Program
Figure 14.6 Kymriah®, Presence in Conferences
Figure 14.7 Product Website Analysis: Yescarta®, Messages for Healthcare Professionals
Figure 14.8 Product Website Analysis: Yescarta®, Messages for Patients
Figure 14.9 Product Website Analysis: Yescarta®, Kite Konnect
Figure 14.10 Product Website Analysis: Yescarta®, Platform for Products Complaints, Reporting Adverse Events and Requesting Medical Information
Figure 14.11 Yescarta®, Presence in Conferences
Figure 16.1 CAR-T Therapy Market Landscape: Non-Industry Participants
Figure 16.2 CAR-T Therapy Market Landscape: Industry Participants
Figure 16.3 CAR-T Therapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 4.1 Key Characteristics of CAR-T Cells
Table 4.2 Comparison Between First and Second-Generation CARs
Table 4.3 Grading Criteria for CRS
Table 4.4 Safety Switches under Development for CAR-T Therapy
Table 4.5 CD19 CAR-T Cells: Preclinical Results
Table 4.6 Other Targets under Clinical / Preclinical Studies for CAR-T Therapy
Table 6.1 CAR-T Therapies: Clinical Pipeline
Table 6.2 CAR-T Therapies: Preclinical Pipeline
Table 6.3 CAR-T Therapies: Information on Constructs of Clinical Candidates,
Table 7.1 CD19 CAR-T Therapies: Competitive Landscape
Table 7.2 CD19 CAR-T Therapies: Clinical Outcomes
Table 7.3 BCMA CAR-T Therapies: Competitive Landscape
Table 7.4 BCMA CAR-T Therapies: Clinical Outcomes
Table 7.5 Meso CAR-T Therapies: Competitive Landscape
Table 7.6 GD2 CAR-T Therapies: Competitive Landscape
Table 7.7 CAR-T Therapies: Clinical Trials
Table 7.8 CAR-T Therapies: Principle Investigators
Table 8.1 Kymriah®: Current Status of Development
Table 8.2 Kymriah®: Clinical Trial Endpoints (ALL)
Table 8.3 Kymriah®: Clinical Trial Endpoints (CLL/MM/NHL)
Table 8.4 Yescarta®: Current Status of Development
Table 8.5 Yescarta®: Clinical Trial Endpoints
Table 8.6 Yescarta®: ZUMA-1 Phase II (6 months Follow-Up)
Table 8.7 Yescarta®: ZUMA-1 Phase II Results (≥3 months Follow-Up)
Table 8.8 Yescarta®: ZUMA-1 Phase I & Phase II Results (3 months Follow-Up)
Table 8.9 JCAR Series: Molecules in Clinical Development
Table 8.10 JCAR: CAR-T Design
Table 8.11 JCAR014: Current Status of Development
Table 8.12 JCAR017: Current Status of Development
Table 8.13 JCAR018: Current Status of Development
Table 8.14 JCAR020: Current Status of Development
Table 8.15 JCAR023: Current Status of Development
Table 8.16 JCAR024: Current Status of Development
Table 8.17 JCAR Series: Clinical Trial Endpoints (Phase II)
Table 8.18 JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.19 JCAR: Dosage Regimen
Table 8.20 CBM CAR-T Series: Clinical Products,
Table 8.21 CBM-CD19.1 CAR-T: Current Status of Development
Table 8.22 CBM-CD20 CAR-T: Current Status of Development
Table 8.23 CBM-CD30.1 CAR-T: Current Status of Development
Table 8.24 CBM-EGFR.1 CAR-T: Current Status of Development
Table 8.25 CBM CAR-T Series: Clinical Trial Endpoints
Table 8.26 CBM CAR-T Series: Patent Portfolio
Table 8.27 Takara Bio’s CD19 CAR-T: Current Status of Development
Table 8.28 Takara Bio’s CD19 CAR-T: Clinical Trial Endpoints
Table 8.29 TBI-1501: Dosage Regimen
Table 8.30 AUTO2: Current Status of Development
Table 8.31 AUTO3: Current Status of Development
Table 8.32 Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.33 Sinobioway Cell Therapy’s CD19 CAR-T Therapy: Current Status of Development
Table 8.34 Sinobioway Cell Therapy’s EPCAM CAR-T Therapy: Current Status of Development
Table 8.35 Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.36 Phase I/II or Phase II CAR-T Therapies from the Industry Players
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2 Leukemia: List of Marketed Targeted Therapeutics
Table 9.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 9.4 CAR-T Therapies: Targets under Investigation for Leukemia
Table 9.5 CAR-T Therapies: Targets under Investigation for Lymphoma
Table 9.6 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 9.7 CAR-T Therapies: Targets under Investigation for Multiple Myeloma
Table 9.8 Melanoma: List of Marketed Targeted Therapeutics
Table 9.9 Lung Cancer: List of Marketed Targeted Therapeutics
Table 9.10 CAR-T Therapies: Targets under Investigation for Lung Cancer
Table 9.11 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 9.12 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 9.13 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 9.14 CAR-T Therapies: Targets under Investigation for Ovarian Cancer
Table 9.15 Breast Cancer: List of Marketed Targeted Therapeutics
Table 9.16 CAR-T Therapies: Targets under Investigation for Breast Cancer
Table 10.1 Editas Medicine: CRISPR/Cas9 Technology, Research Publications
Table 10.2 Editas Medicine: Funding Instances
Table 10.3 Editas Medicine: Collaborations
Table 10.4 Intellia Therapeutics: CRISPR/Cas9 Technology, Research Publications
Table 10.5 Intellia Therapeutics: Funding Instances
Table 10.6 Intellia Therapeutics: Collaborations
Table 10.7 CRISPR Therapeutics: CRIPSR/Cas9 Technology, Research Publications
Table 10.8 CRISPR Therapeutics: Funding Instances
Table 10.9 CRISPR Therapeutics: Collaborations
Table 10.10 Cellectis: Funding Instances
Table 10.11 Cellectis: Collaborations
Table 10.12 bluebird bio: megaTAL Technology, Research Publications
Table 10.13 bluebird bio: Funding Instances
Table 10.14 bluebird bio: Collaborations
Table 10.15 Sangamo Therapeutics: Funding Instances
Table 10.16 Sangamo Therapeutics: Collaborations
Table 10.17 Celyad: Funding Instances
Table 10.18 Celyad: Collaborations
Table 10.19 Intrexon: Funding Instances
Table 10.20 Intrexon: Collaborations
Table 10.21 Bellicum Pharmaceuticals: Key Switch Technologies
Table 10.22 Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 10.23 Bellicum Pharmaceuticals: Funding Instances
Table 10.24 Bellicum Pharmaceuticals: Collaborations
Table 10.25 Theravectys: Funding Instances
Table 10.26 Technologies For CAR-T Safety Enhancement
Table 10.27 Formula Pharmaceuticals: Collaborations
Table 10.28 Celyad: Collaborations
Table 11.1 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 11.2 Cell Therapy Manufacturing: Contract Manufacturers
Table 12.1 Price of Marketed Gene / Cell Therapies
Table 12.2 Price of Marketed Targeted Drugs
Table 12.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 12.4 CAR-T Therapies: Reimbursement Landscape
Table 13.1 CAR-T Therapies: List of Forecasted Molecules
Table 14.1 Kymriah: Drug Overview
Table 14.2 Yescarta: Drug Overview
Table 15.1 Autolus: Company Profile
Table 15.2 bluebird bio: Company Profile
Table 15.3 CARsgen Therapeutics: Company Profile
Table 15.4 Celgene: Company Profile
Table 15.5 Cell Medica: Company Profile
Table 15.6 Cellectis: Company Profile
Table 15.7 Cellular Biomedicine Group: Company Profile
Table 15.8 Innovative Cellular Therapeutics: Company Profile
Table 15.9 Kite Pharma: Company Profile
Table 15.10 Novartis: Company Profile
Table 15.11 Sinobioway Cell Therapy: Company Profile
Table 15.12 Takara Bio: Company Profile
Table 15.13 ZIOPHARM Oncology: Company Profile
Table 18.1 CAR-T Pipeline: Distribution by Type of Developer
Table 18.2 CAR-T Therapy Pipeline: Distribution by Phase of Development
Table 18.3 CAR-T Therapy Pipeline: Distribution by Target Therapeutic Area
Table 18.4 CAR-T Therapy Pipeline: Popular Target Indications
Table 18.5 CAR-T Therapy Pipeline: Distribution by Target Antigen
Table 18.6 CAR-T Therapy Pipeline: Distribution by Source of T-Cells
Table 18.7 CAR-T Therapy Pipeline: Distribution by Route of Administration
Table 18.8 CAR-T Therapy Pipeline: Active Industry Players in Clinical Development
Table 18.9 CAR-T Therapy Pipeline: Active Industry Players in Preclinical Development
Table 18.10 CAR-T Pipeline: Active Non-Industry Players in Clinical Development
Table 18.11 CAR-T Pipeline: Active Non-Industry Players in Preclinical Development
Table 18.12 CAR-Construction: Distribution by Generation of CAR-T Therapies
Table 18.13 CAR-Construction: Distribution by Type of scFv Used in CAR-T Therapies
Table 18.14 CAR-Construction: Distribution by Type of Vector
Table 18.15 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Table 18.16 CAR-T Therapies: Popular Targets in Hematological Cancer
Table 18.17 CAR-T Therapies: Popular Targets in Solid Tumor
Table 18.18 CAR-T Clinical Trials: Cumulative Trend (Pre-2012-2018)
Table 18.19 CAR-T Clinical Trials: Geographic Landscape (Pre-2016 and 2018)
Table 18.20 CAR-T Therapies: Distribution of Clinical Trials by Phase of Development
Table 18.21 CAR-T Therapies: Distribution of Clinical Trials by Patient Segment
Table 18.22 CAR-T Therapies: Distribution of Clinical Trials by Type of Therapy
Table 18.23 Overall CAR-T Therapy Market Forecast, 2018-2030: Conservative Scenario (USD Billion)
Table 18.24 Overall CAR-T Therapy Market Forecast, 2018-2030: Base Scenario (USD Billion)
Table 18.25 Overall CAR-T Therapy Market Forecast, 2018-2030: Optimistic Scenario (USD Billion)
Table 18.26 CAR-T Therapy Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 18.27 CAR-T Therapy Market: Distribution by Target Indication, 2025 and 2030 (USD Billion)
Table 18.28 Kymriah® (Novartis) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.29 Kymriah® (Novartis) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.30 Kymriah® (Novartis) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.31 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.32 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.33 Yescarta® (Gilead Sciences) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.34 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.35 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.36 bb2121 (Celgene / bluebird bio) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.37 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.38 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.39 MB-CART19.1 (Miltenyi Biotec / Shanghai Children's Medical Center) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.40 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.41 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.42 CD19 CAR-T (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.43 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.44 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.45 GPC3 CAR-T (Shanghai GeneChem) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.46 TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.47 TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.48 TBI-1501 (Takara Bio / Jichi Medical University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.49 JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.50 JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.51 JCAR017 (Juno Therapeutics / Celgene) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.52 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.53 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.54 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.55 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.56 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.57 PCAR-019 (PersonGen BioTherapeutics) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.58 AUTO2 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.59 AUTO2 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.60 AUTO2 (Autolus) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.61 AUTO3 (Autolus) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.62 AUTO3 (Autolus) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.63 AUTO3 (Autolus) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.64 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.65 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.66 BCMA CAR-T (The Beijing Pregene Science and Technology / Henan Cancer Hospital) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.67 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.68 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.69 CD19 CAR-T (The Pregene (ShenZhen) Biotechnology Company / Henan Cancer Hospital) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.70 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.71 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.72 CD19 CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology / The First Affiliated Hospital of Soochow University) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.73 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.74 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.75 LCAR-B38M CAR-T (Nanjing Legend Biotech) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.76 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Conservative Scenario (USD Million)
Table 18.77 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 18.78 CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
Table 18.79 CAR-T Therapy Market Forecast, 2018, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
The following companies and organizations have been mentioned in the report: Abramson Cancer Center
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES
.png)
.png)
.png)
.png)
.png)
.png)